PALISADE BIO INC (PALI) Forecast, Price Target & Analyst Ratings

Name: PALISADE BIO INC (PALI) Analyst Consensus Rating
Brand: PALISADE BIO INC
Rating: 8.5 (13 reviews)

NASDAQ:PALI • US6963894026

1.57 USD

-0.21 (-11.8%)

Last: Mar 31, 2026, 01:02 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PALISADE BIO INC (PALI).

Consensus Price Target

Price Target

$12.24

+ 679.62% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 11, 2026
Period: Q1 / 2026
EPS Estimate: -$0.04
Revenue Estimate

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

84.62%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$12.24

Upside

+ 679.62%

From current price of $1.57 to mean target of $12.24, Based on 13 analyst forecasts

Low

$5.05

Median

$8.16

High

$26.25

Price Target Revisions

1 Month

-8.86%

3 Months

2.86%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for PALI. The average price target is 12.24 USD. This implies a price increase of 679.62% is expected in the next year compared to the current price of 1.57.

The average price target has been revised upward by 2.86% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

84.62%

PALI was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about PALI.

In the previous month the buy percentage consensus was at a similar level.

PALI was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-03-26	HC Wainwright & Co.	Initiate	Buy
2026-02-25	Stifel	Initiate	Buy
2026-01-09	B. Riley Securities	Initiate	Buy
2025-12-30	Clear Street	Initiate	Buy
2025-12-29	Piper Sandler	Initiate	Overweight
2025-05-13	Brookline Capital	Maintains	Buy -> Buy
2024-11-20	Brookline Capital	Initiate	Buy
2024-11-13	Maxim Group	Maintains	Buy -> Buy
2024-05-01	Maxim Group	Reiterate	Buy -> Buy
2024-04-16	Maxim Group	Maintains	Buy -> Buy
2023-11-17	Maxim Group	Upgrade	Hold -> Buy
2023-05-16	Ladenburg Thalmann	Maintains	Buy -> Buy
2023-03-30	Maxim Group	Upgrade	Hold -> Buy
2022-08-19	Maxim Group	Downgrade	Buy -> Hold
2022-02-02	Ladenburg Thalmann	Initiate	Buy
2021-08-31	Maxim Group	Initiate	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 11, 2026
Period: Q1 / 2026
EPS Estimate: -$0.04
Revenue Estimate
Revenue Q2Q: N/A
EPS Q2Q: 92.40%
Number of Analysts: 7

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

0.00%

EPS (3 Months)

0.00%

Next Earnings Summary

PALI is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.04 USD and the consensus revenue estimate is 0 USD.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth	-100.00%		250K	-100.00%				82.652M	84.727M 2.51%	344.76M 306.91%	61.059M -82.29%	167.62M 174.52%	442.98M 164.28%
EBITDA YoY % growth	-11.735M -10.88%	-15.308M -30.45%	-12.841M 16.12%	N/A -15.69%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-11.737M -9.94%	-15.311M -30.45%	-12.845M 16.11%	-15.642M -15.68%	-12.11M 18.50%	-41.232M -240.47%	-55.764M -35.25%	-82.918M -48.69%	-77.883M 6.07%	-23.561M 69.75%	-40.445M -71.66%	45.415M 212.29%	277.62M 511.30%
Operating Margin	N/A	N/A	-5,138.00%	N/A	N/A	N/A	N/A	-100.32%	-91.92%	-6.83%	-66.24%	27.09%	62.67%
EPS YoY % growth	N/A	-247.95 91.73%	-29.10 88.26%	-11.90 59.53%	-0.78 87.18%	-0.39 74.17%	-0.46 -18.98%	-0.37 20.88%	-0.31 15.28%	-0.04 86.07%	0.10 323.53%	0.52 431.58%	1.76 241.58%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	-0.04 92.40%	-0.05 91.28%	-0.08 79.98%	-0.10 -24.95%
Revenue Q2Q % growth
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-5.979M -158.82%	-8.509M -199.31%	-14.477M -342.51%	-20.141M -415.85%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

20.66%

EPS Next 5 Year

14.54%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PALISADE BIO INC / PALI Forecast FAQ

What is the average price target for PALISADE BIO INC (PALI) stock?

13 analysts have analysed PALI and the average price target is 12.24 USD. This implies a price increase of 679.62% is expected in the next year compared to the current price of 1.57.

Can you provide the upcoming earnings date for PALISADE BIO INC?

PALISADE BIO INC (PALI) will report earnings on 2026-05-11.

What are the consensus estimates for PALISADE BIO INC (PALI) next earnings?

The consensus EPS estimate for the next earnings of PALISADE BIO INC (PALI) is -0.04 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for PALISADE BIO INC stock?

The consensus rating for PALISADE BIO INC (PALI) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.

Analyst forecast overview

Forecast Snapshot